Bengaluru-based biotech company Pandorum Technologies specializes in programmable regenerative medicine, and the company announced an $18 million Series B funding round led by Protons Corporate to advance its offerings and expand its reach.
Pandorum leverages biology, engineering and computation to develop tunable, regenerative exosome therapies that essentially revert tissue states like inflammation and fibrosis toward functional recovery. The company will invest its new capital in the clinical development of its therapies, scaling global manufacturing and expanding operations across the U.S., Japan and the Middle East.
“Our approach treats tissue health, disease and degeneration as a navigational challenge within an information-constrained biological landscape,” Dr. Tuhin Bhowmick, Pandorum CEO and co-founder, said in a statement. “This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair, aligned with Pandorum’s vision — to heal fast and age slow.”
